Lack of Long-term Effects of In Utero Exposure to Zidovudine Among Uninfected Children Born to HIV-Infected Women
Open Access
- 13 January 1999
- journal article
- clinical trial
- Published by American Medical Association (AMA) in JAMA
- Vol. 281 (2) , 151-157
- https://doi.org/10.1001/jama.281.2.151
Abstract
Since the results of the successful perinatal human immunodeficiency virus (HIV) prevention trial, the Pediatric AIDS Clinical Trials Group Protocol 076 (PACTG 076), which included an intensive regimen of zidovudine, were reported in February 1994, use of zidovudine for prevention of mother-to-infant transmission of HIV has become widespread in the United States.1,2 However, the late effects of perinatal exposure to antiretroviral drugs on the subsequent health of uninfected children are unknown and can be determined only by the long-term follow-up of children exposed in utero.Keywords
This publication has 7 references indexed in Scilit:
- Lack of Tumors in Infants With Perinatal HIV-1 Exposure and Fetal/Neonatal Exposure to ZidovudineJAIDS Journal of Acquired Immune Deficiency Syndromes, 1999
- Safety of the maternal–infant zidovudine regimen utilized in the Pediatric AIDS Clinical Trial Group 076 StudyAIDS, 1998
- Acceptability and impact of zidovudine for prevention of mother-to-child human immunodeficiency virus–1 transmission in FranceThe Journal of Pediatrics, 1997
- Transplacental Effects of 3'-Azido-2',3'-Dideoxythymidine (AZT): Tumorigenicity in Mice and Genotoxicity in Mice and MonkeysJNCI Journal of the National Cancer Institute, 1997
- Reduction of Maternal-Infant Transmission of Human Immunodeficiency Virus Type 1 with Zidovudine TreatmentNew England Journal of Medicine, 1994
- A Multicenter Trial of Oral Zidovudine in Children with Advanced Human Immunodeficiency Virus DiseaseNew England Journal of Medicine, 1991
- Development of normalized curves for the international growth reference: historical and technical considerationsThe American Journal of Clinical Nutrition, 1987